Top
image credit: Unsplash

Three-drug combination reduces all-cause mortality in COPD patients

March 18, 2020

Category:

Once-daily treatment of patients with chronic obstructive pulmonary disease (COPD) with an inhaler combining fluticasone furoate (FF), umeclidinium (UMEC) and vilanterol (VI) reduced all-cause mortality by 42 percent, according to new research published online in the American Thoracic Society’s American Journal of Respiratory and Critical Care Medicine.

In “Reduction in All-Cause Mortality With Fluticasone Furoate/Umeclidinium/Vilanterol in COPD Patients,” David A. Lipson, MD, and co-authors report on an expanded post hoc analysis of data from the multicenter, 37-country Phase 3 IMPACT trial, which includes additional vital status data from patients one year after the start of the study.

Read More on The Medical News